0001180145-18-000056.txt : 20181116 0001180145-18-000056.hdr.sgml : 20181116 20181116100126 ACCESSION NUMBER: 0001180145-18-000056 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181114 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20181116 DATE AS OF CHANGE: 20181116 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cardiovascular Systems Inc CENTRAL INDEX KEY: 0001180145 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411698056 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52082 FILM NUMBER: 181188848 BUSINESS ADDRESS: STREET 1: 1225 OLD HWY 8 NW CITY: ST. PAUL STATE: MN ZIP: 55112 BUSINESS PHONE: 651-259-1600 MAIL ADDRESS: STREET 1: 1225 OLD HWY 8 NW CITY: ST. PAUL STATE: MN ZIP: 55112 FORMER COMPANY: FORMER CONFORMED NAME: REPLIDYNE INC DATE OF NAME CHANGE: 20020813 8-K 1 a8-k111418xasm.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 8-K
 
 CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2018
 
Cardiovascular Systems, Inc.
(Exact name of Registrant as Specified in its Charter)
 
 
 
 
 
 
Delaware
 
000-52082
 
41-1698056
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
1225 Old Highway 8 NW
St. Paul, Minnesota 55112-6416
(Address of Principal Executive Offices and Zip Code)
(651) 259-1600
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o




Item 5.07    Submission of Matters to a Vote of Security Holders.

The Company held its 2018 Annual Meeting of Stockholders on November 14, 2018. Set forth below is a brief description of each matter voted upon at the meeting and the voting results with respect to each matter.

1.
Proposal to elect Class I directors to hold office until the fiscal 2021 Annual Meeting of Stockholders:
Class I Director’s Name
 
For
 
Against
 
Abstain
 
Broker Non-Votes
Scott Bartos
 
24,634,393
 
1,059,761
 
475
 
3,824,819
Edward Brown
 
25,515,183
 
178,971
 
475
 
3,824,819
Augustine Lawlor
 
24,435,494
 
1,258,660
 
475
 
3,824,819

2.
Proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending June 30, 2019.
For
 
Against
 
Abstain
 
Broker Non-Votes
29,234,451
 
277,182
 
7,815
 
0

3.
Proposal to cast a non-binding advisory vote on the compensation paid to the Company’s named executive officers.
For
 
Against
 
Abstain
 
Broker Non-Votes
23,240,661
 
2,442,118
 
11,850
 
3,824,819





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 16, 2018
CARDIOVASCULAR SYSTEMS, INC.
By:
 
/s/ Alexander Rosenstein
Alexander Rosenstein
General Counsel and Corporate Secretary